Synthesis and anti-HCV activity of N9,5′-cyclo-3-(β- D-ribofuranosyl)-8-azapurin-2-one derivatives

Nucleosides, Nucleotides and Nucleic Acids

Volumn 24, Issue 10-12, 2005, Pages 1531-1542

  Hassan, Abdalla E A ^a   Wang, Peiyuan ^a   McBrayer, Tamara ^a   Tharnish, Philip ^a   Stuyver, Lieven ^a   Otto, Michael J ^a   Watanabe, Kyoichi A ^a   Schinazi, Raymond F ^b  

^a PHARMASSET INC   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

N9,5 Anhydro isonucleosides; N9,5 cyclo 3 ( D ribofuranosyl) 8 azapurine nucleosides; Potential anti HCV nucleosides

Indexed keywords

9,5' CYCLO 1 METHYL 3 (BETA DEXTRO RIBOFURANOSYL) 8 AZAXANTHINE; 9,5' CYCLO 3 (BETA DEXTRO RIBOFURANOSYL) 8 AZAXANTHINE; 9,5' CYCLO 3 BETA DEXTRO RIBOFURANOSYL 8 AZA 6 THIOXANTHINE; ANTIVIRUS AGENT; N9,5' CYCLO 3 (BETA DEXTRO RIBOFURANOSYL) 6 METHYLAMINO 8 AZAPURIN 2 ONE; PURINE DERIVATIVE; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG SYNTHESIS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; METHODOLOGY; NONHUMAN; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ADENOSINE; ANTIVIRAL AGENTS; HEPACIVIRUS; HUMANS; PURINES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 29244433081     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770500265802     Document Type: Article

References (9)

1. Alter, M.J.; Kruszon-Moran, D.; Nainan, O.V.; McQuillan, G.M.; Gao F.; Moyer, L.A.; Kaslow, R.A.; Margolis, H.S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 1999, 341, 556-562.
2. Collier, J.; Chapman, R. Combination therapy with interferon-alpha and ribavirin for hepatitis C: Practical treatment issues. BioDrugs 2001, 15, 225-238.
3. Di Bisceglie, A.M.; McHutchison, M.J.; Rice, C.M. New therapeutic strategies for hepatitis C. Hepatology 2002, 285, 224-231.
4. 3,5′-cyclo-4- (β-D-ribofuranosyl)-vic-triazolo[4,5-b]pyridin-5-one: A novel compound with potential anti-hepatitis C virus activity. J. Med. Chem. 2004, 47, 6100-6103.
5. 3,5′-cyclo-4-(β-D- ribofuranosyl)-vic-triazolo[4,5-b]pyridin-5-one and its 3′-deoxy analogue as potential anti-hepatitis C virus agents. Nucleosides, Nucleotides & Nucleic Acids 2005, 24, 957-960.
6. 3,5′-anhydro-4-(β-D- ribofuranosyl)-8-azapurin-2-ones. Nucleosides, Nucleotides & Nucleic Acids 2005, 24, 961-964.
7. Sasaki, T.; Minamoto, K.; Kino, M.; Mizuno, T. Reactions of the derivatives of 5-bromopyrimidine nucleosides with sodium azide. J. Org. Chem. 1976, 41, 1100-1104.
8. Stuyver, L.J.; McBrayer, T.R.; Tharnish, P.M.; Hassan, A.E.A.; Chu, C.K.; Pankiewicz, K.W.; Watanabe, K.A.; Schinazi, R.F.; Otto, M.J. Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh cells after exposure to nucleotide anti-metabolites. J. Virol. 2003, 77, 10689-10694.
9. Schinazi, R.F.; Sommadossi. J.P.; Saalmann, V.; Cannon, D.L.; Xie, M.-W.; Hart, G.C.; Smith, G.A.; Hahn, E.F. Activity of 3′-azido-3′- deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1990, 34(6), 1061-1067.